An open-label, randomised, comparative, multicentre study of the immunogenicity and safety of ZOSTAVAX when administered by intramuscular route or subcutaneous route to subjects >=50 years of age.
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Varicella zoster virus vaccine live (Primary) ; Varicella zoster virus vaccine live (Primary)
- Indications Herpes zoster
- Focus Pharmacodynamics
- Sponsors Merck Sharp & Dohme; sanofi pasteur MSD
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Apr 2013 Planned End Date changed from 1 Apr 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 20 Sep 2012 Planned end date changed from 1 Jun 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.